title: [Effects of fluvastatin on expression of p38 mitogen-activated protein kinase in renal tissue of chronic graft versus host disease lupus nephritis in mice].
abstract: OBJECTIVE
  To explore the effects of fluvastatin on expression of p38 mitogen-activated protein kinase (p38MAPK) in renal tissue of chronic graft versus host disease (cGVHD) lupus nephritis in mice.
  
  
  METHODS
  Mice were randomly divided into 4 groups of model, low-dose fluvastatin intervention (5 mg×kg(-1)×d(-1)), high-dose fluvastatin intervention (10 mg×kg(-1)×d(-1)) and normal control. The 24 h total amount of urine protein was evaluated by biuret reaction colorimetric assay. And the protein and mRNA expression levels of p38MAPK, p-p38MAPK and TGF-β1 in renal tissue were detected by immunohistochemistry, Western blot and reverse transcription-polymerase chain reaction (RT-PCR) respectively.
  
  
  RESULTS
  Compared with the normal control group, 24 h total amount of urine protein, protein and mRNA expression levels of p38MAPK, p-p38MAPK and TGF-β1 increased significantly in the model group respectively ((7.84 ± 0.36) vs (1.15 ± 0.15) mg/24 h, 0.81 ± 0.03 vs 0.50 ± 0.01, 0.69 ± 0.02 vs 0.10 ± 0.01, 0.76 ± 0.02 vs 0.28 ± 0.02, 0.84 ± 0.04 vs 0.25 ± 0.02, 0.82 ± 0.04 vs 0.12 ± 0.02, all P < 0.01). Fluvastatin treatment suppressed markedly their increased expressions (P < 0.05). And high-dose fluvastatin treatment suppressed more significantly than low-dose group (P < 0.05).
  
  
  CONCLUSIONS
  The renal protection effect of fluvastatin may be achieved by inhibiting the signal pathway of p38MAPK.
authors.affiliation: Department of Rheumatology, Zhongda Hospital, Southeast University, Nanjing 210009, China.
authors.forename: Qin
authors.initials: Q
authors.lastname: Zhang
authors.affiliation: Email: wmm3272142@163. com.
authors.forename: Meimei
authors.initials: M
authors.lastname: Wang
mesh_terms: D000818:Animals; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology*; D000077340:Fluvastatin; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000201:enzymology*; D007211:Indoles / Q000494:pharmacology*; D008181:Lupus Nephritis / Q000188:drug therapy / Q000201:enzymology*; D020935:MAP Kinase Signaling System; D051379:Mice; D053773:Transforming Growth Factor beta1; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism*
chemical_list: D005229:Fatty Acids, Monounsaturated; D007211:Indoles; D053773:Transforming Growth Factor beta1; D000077340:Fluvastatin; D048051:p38 Mitogen-Activated Protein Kinases